Medical devices and healthcare corporation Abbott Laboratories (NYSE:ABT) recently announced that its new cardiac mapping platform, the EnSite™ X EP System with EnSite Omnipolar Technology (OT), has received clearance from the U.S. Food and Drug Administration (FDA). The mapping platform is aimed at assisting doctors to better treat abnormal heart rhythms. Following the news, shares of the company declined 1.5% on Wednesday. The stock pared its loss slightly to close at $133.76 in the extended trading session.
https://www.tipranks.com/news/abbotts-cardiac-mapping-system-receives-fda-approval?utm_source=advfn.com&utm_medium=referral
Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Abr 2022 até Mai 2022 Click aqui para mais gráficos Abbott Laboratories.
Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Mai 2021 até Mai 2022 Click aqui para mais gráficos Abbott Laboratories.